McCulloch D, Brown C, Iland H. *Onco Targets Ther.* 2017;10:1585--1601.

On page 1594, [Table 3](#t3-ott-10-2511){ref-type="table"} contained several errors. The correct table is presented below and the notes section has been updated throughout the table accordingly.

###### 

Commonly employed current treatment regimens in APL, stratified by risk category

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protocol                    Induction                                                                                                                                                   Consolidation                                                                                                                                                                                                                          Maintenance
  --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------
  **Low-intermediate risk**                                                                                                                                                                                                                                                                                                                                                                                                      

  **APL0406**^39^             ATRA 45 mg/m^2^/d PO + ATO 0.15 mg/kg/d IV until CR (max 60 days)                                                                                           ATRA 45 mg/m^2^/d PO for 14 days then rest for 14 days ×7 cycles + ATO 0.15 mg/kg/d IV for 5 days per week for 4 weeks then rest for 4 weeks ×4 cycles                                                                                 Nil

  **LPA2005**^37^             ATRA 45 mg/m^2^/d PO[a](#tfn1-ott-10-2511){ref-type="table-fn"} until CR + Idarubicin 12 mg/m^2^/d d2, 4, 6, 8[b](#tfn2-ott-10-2511){ref-type="table-fn"}   1\. ATRA 45 mg/m^2^/d PO d1--15 + Idarubicin 5^low^/7^int^ mg/m^2^/d d1--4\                                                                                                                                                            ATRA 45 mg/m^2^/day PO d1--15 every 3 months\
                                                                                                                                                                                          2. ATRA 45 mg/m^2^/d PO d1--15 + MTZ 10 mg/m^2^/d d1--3\                                                                                                                                                                               MTX 15 mg/m^2^/wk IM d15--90\
                                                                                                                                                                                          3. ATRA 45 mg/m^2^/d PO d1--15 + Idarubicin 12 mg/m^2^/d d1^low^ or d1--2^int^                                                                                                                                                         6-MP 50 mg/m^2^/d PO d15--90 for 2 years

  **High risk**                                                                                                                                                                                                                                                                                                                                                                                                                  

  **APML4**^38^               ATRA 45 mg/m^2^/day PO d1--36\                                                                                                                              1\. ATRA 45 mg/m^2^/d PO days 1--28 + ATO 0.15 mg/kg/d IV d1--28\                                                                                                                                                                      ATRA 45 mg/m^2^/day\
                              ATO 0.15 mg/kg/day IV d9--36 Idarubicin 6--12 mg/m^2^ d2, 4, 6, 8[c](#tfn3-ott-10-2511){ref-type="table-fn"},[d](#tfn4-ott-10-2511){ref-type="table-fn"}    2. ATRA 45 mg/m^2^/d PO d1--7, 15--21 and 29--35 + ATO 0.15 mg/kg/d IV for 5 days per week for 5 weeks                                                                                                                                 PO d1--14 every 90 days\
                                                                                                                                                                                                                                                                                                                                                                                                                                 MTX 5--15 mg/m^2^/wk PO d15--90\
                                                                                                                                                                                                                                                                                                                                                                                                                                 6-MP 50--90 mg/m^2^/d PO\
                                                                                                                                                                                                                                                                                                                                                                                                                                 d15--90 ×8 cycles

  **Study C9710**^36^         ATRA 45 mg/m^2^/d PO until CR (max 90 days) + Cytarabine 200 mg/m^2^ IV d3--9 + DNR 50 mg/m^2^ IV d3--6                                                     1\. ATO 0.15 mg/kg/d IV for 5 days per week for 5 weeks ×2 cycles\                                                                                                                                                                     ATRA 45 mg/m^2^/d PO days 1--7 repeated on alternate weeks\
                                                                                                                                                                                          2. ATRA 45 mg/m^2^/d PO days 1--7 + DNR 50 mg/m^2^ IV d1--3 ×2 cycles                                                                                                                                                                  MTX 20 mg/m^2^/wk PO 6-MP 60 mg/m^2^/d PO for 1 year

  **APL2000**^96^             ATRA 45 mg/m^2^/d PO until CR + Cytarabine 200 mg/m^2^ d1--7 + DNR 60 mg/m^2^ d1--3                                                                         1\. DNR 60 mg/m^2^/d d1--3 + Cytarabine 200 mg/m^2^/d d1--7\                                                                                                                                                                           ATRA 45 mg/m^2^/day PO d1--15 every 90 days\
                                                                                                                                                                                          2. DNR 45 mg/m^2^/d d1--3 + Cytarabine 2 g/m^2^/12h d1--5 (\<50 years) or Cytarabine 1.5 g/m^2^/12h d1--5 (50--60 years) or Cytarabine 1.0 g/m^2^/12h d1--4 (\>60 years) + 5 doses of MTX 15 mg/Cytarabine 50 mg/Depomedrol given IT   MTX 15 mg/m^2^/wk PO d15--90\
                                                                                                                                                                                                                                                                                                                                                                                                                                 6-MP 50 mg/m^2^/d PO d15--90 for 2 years

  **LPA2005**^37^             ATRA 45 mg/m^2^/d PO[a](#tfn1-ott-10-2511){ref-type="table-fn"} until CR + Idarubicin 12 mg/m^2^/d d2, 4, 6, 8[b](#tfn2-ott-10-2511){ref-type="table-fn"}   1\. ATRA 45 mg/m^2^/d PO d1--15 + Idarubicin 5 mg/m^2^/d d1--4 + Cytarabine 1 g/m^2^/d d1--4[e](#tfn5-ott-10-2511){ref-type="table-fn"}\                                                                                               ATRA 45 mg/m^2^/day PO d1--15 every 3 months\
                                                                                                                                                                                          2. ATRA 45 mg/m^2^/d PO d1--15 + MTZ 10 mg/m^2^/d d1--5\                                                                                                                                                                               MTX 15 mg/m^2^/wk IM d15--90\
                                                                                                                                                                                          3. ATRA 45 mg/m^2^/d PO d1--15 + Idarubicin 12 mg/m^2^/d d1 + Cytarabine 150 mg/m^2^/8h d1--4[e](#tfn5-ott-10-2511){ref-type="table-fn"}                                                                                               6-MP 50 mg/m^2^/d PO d15--90 for 2 years
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

ATRA 25 mg/m^2^/d if \<20 years.

If \>70 years Idarubicin 12 mg/m^2^ d8 omitted.

Prednisolone 1 mg/kg/day PO on d1--10 or until WCC \<1×10^9^/L.

Age adjusted idarubicin; 1--60 years, 12 mg/m^2^; 61--70 years, 9 mg/m^2^; \>70 years, 6 mg/m^2^.

If \>60 years no Cytarabine given in consolidation and Idarubicin dose as per intermediate risk patients described in LPA2005 low-int risk protocol.

**Abbreviations:** Low, low risk patients; Int, intermediate risk patients; MTX, Methotrexate; 6-MP, Mercaptopurine; DNR, Daunorubicin; MTZ, Mitoxantrone; IT, intrathecal; IM, intramuscular; IV, intravenous; PO, per os (orally).
